2. Immunology/Inflammation
  3. MHC
  4. WT1 126-134 peptide acetate

WT1 126-134 peptide acetate is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide acetate is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide acetate/HLA-A0201 complex has an extremely high affinity (Kd = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide acetate can be used as a vaccine for T cells or as a target for antibodies.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

WT1 126-134 peptide acetate

WT1 126-134 peptide acetate Chemical Structure

Size Stock
5 mg Check price and availability
10 mg Check price and availability
25 mg Check price and availability

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of WT1 126-134 peptide acetate:

WT1 126-134 peptide acetate Related Antibodies

Top Publications Citing Use of Products

View All MHC Isoform Specific Products:

View All Isoforms
MHC I MHC II

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

WT1 126-134 peptide acetate is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide acetate is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide acetate/HLA-A0201 complex has an extremely high affinity (Kd = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide acetate can be used as a vaccine for T cells or as a target for antibodies[1][2][3].

In Vivo

WT1 126-134 peptide (100 μg, emulsified with incomplete Freund’s adjuvant, i.p., once a week for 2 weeks) acetate induces epitope-specific CTL, but fails to produce a significant anti-tumor effect in the TRAMP-C2 model[1].
WT1 126-134 peptide (100 μg, emulsified with incomplete Freund’s adjuvant, i.p., once a week for 3 weeks) acetate combined with the auxiliary peptide (WT135-52) significantly enhances CTL induction and delays tumor growth induced by mWT1-C1498 cells in mice[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: TRAMP-C2 murine prostate cancer cell syngeneic tumor model established in male C57BL/6 mice[1]
Dosage: 100 μg, emulsified with incomplete Freund’s adjuvant
Administration: Intraperitoneal injection (i.p.), once a week for 2 weeks
Result: Induced peptide-specific CTL, but was unable to effectively recognize the naturally expressed WT1 protein.
Failed to produce significant anti-tumor effects.
Molecular Weight

1108.31 (free base)

Formula

C52H77N13O12S·xC2H4O2
Appearance

Solid

Sequence

Arg-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu
Sequence Shortening

RMFPNAPYL
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

WT1 126-134 peptide acetate Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

WT1 126-134 peptideMHCMajor Histocompatibility ComplexInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
WT1 126-134 peptide acetate
Cat. No.:
HY-P11084A
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.